Clinical trial NCT01572038: A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer
Official title: A Multicenter, Open-Label, Single-Arm Study of Pertuzumab in Combination With Trastuzumab and a Taxane in First Line Treatment of Patients With HER2-Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Breast Neoplasms
Lead sponsor: Hoffmann-La Roche
Sponsor class: INDUSTRY
First posted: 2012-04-05
Enrollment: 1436
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This multicenter, open-label, single-arm, Phase IIIb study will evaluate the safety and tolerability of pertuzumab in combination with trastuzumab (Herceptin) and a taxane (docetaxel, paclitaxel or nab-paclitaxel) in first-line treatment in participants with metastatic or locally recurrent HER2-positive breast cancer. Participants will receive pertuzumab intravenously (IV) and trastuzumab (Herceptin) IV plus a taxane in cycles of 3 weeks each until predefined study end, unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first.


Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically confirmed adenocarcinoma of the breast with metastatic or locally recurrent disease not amenable to curative resection
* HER2-positive breast cancer
* Eastern cooperative Oncology Group (ECOG) performance status 0, 1 or 2
* LVEF of at least 50 percent (%)

Exclusion Criteria:

* Previous systemic non-hormonal anti-cancer therapy for metastatic or locally recurrent disease
* Disease-free interval from completion of adjuvant or neoadjuvant systemic non-hormonal treatment to recurrence less than or equal to (\</=) 6 months
* Previous approved or investigative anti-HER2 agents in any breast cancer treatment setting, except for trastuzumab and/or lapatinib in the adjuvant or neoadjuvant setting
* Disease progression while receiving trastuzumab and/or lapatinib in the adjuvant or neoadjuvant setting
* History of persistent Grade 2 or higher (National Cancer Institute Common Toxicity Criteria \[NCI-CTC\], Version 4.0) hematological toxicity resulting from previous adjuvant or neoadjuvant therapy
* Central nervous system (CNS) metastases
* Current peripheral neuropathy of Grade 3 or greater (NCI-CTC, version 4.0)
* History of other malignancy within the last 5 years prior to first study drug administration, except for carcinoma in situ of the cervix or basal cell carcinoma
* Inadequate bone marrow, liver or renal function
* Uncontrolled hypertension
* Hepatitis B, hepatitis C or Human Immunodeficiency Virus (HIV) infection

Primary outcomes:
measure: Overview of the Number of Participants With at Least One Treatment-Emergent Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v4.0)
timeFrame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Number of Participants Who Died Over the Course of the Study by Reported Cause of Death (Adverse Events Leading to Death by System Organ Class and Preferred Term)
timeFrame: The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
measure: Number of Participants Who Died Within 6 Months of Starting Study Treatment by Reported Cause of Death (Adverse Events Leading to Death by System Organ Class and Preferred Term)
timeFrame: The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
measure: Number of Participants With Grade ≥3 Treatment-Emergent Adverse Events, Occurring in ≥1% of Participants by System Organ Class and Preferred Term
timeFrame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Number of Participants With Treatment-Emergent Adverse Events of Any Grade That Were Related to Study Treatment (Pertuzumab, Trastuzumab, or Taxane), Occurring in ≥10% of Participants by System Organ Class
timeFrame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Number of Participants With Grade ≥3 Treatment-Emergent Adverse Events That Were Related to Study Treatment (Pertuzumab, Trastuzumab, or Taxane), Occurring in ≥0.5% of Participants by Preferred Term
timeFrame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Number of Participants With Treatment-Emergent Adverse Events Leading to Discontinuation of Study Treatment (Pertuzumab, Trastuzumab, or Taxane), Occurring in ≥0.2% of Participants by Preferred Term
timeFrame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Number of Participants With Treatment-Emergent Adverse Events Leading to Dose Interruption of Study Treatment (Pertuzumab, Trastuzumab, or Taxane), Occurring in ≥0.5% of Participants by Preferred Term
timeFrame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Number of Participants With Treatment-Emergent Adverse Events to Monitor of Any Grade, Occurring in ≥5% of Participants by Category
timeFrame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Number of Participants With Grade ≥3 Treatment-Emergent Adverse Events to Monitor, Occurring in ≥0.5% of Participants by Category and Preferred Term
timeFrame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Number of Participants With Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term
timeFrame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Subgroup Analysis by Region of Enrollment: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab
timeFrame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Subgroup Analysis by Age (≤65 vs. >65 Years): Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), TEAEs Leading to Death, Grade ≥3 TEAEs, Any-Grade and Grade ≥3 TEAEs Related to Pertuzumab, and TEAEs to Monitor
timeFrame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Subgroup Analysis by Taxane Chemotherapy: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), TEAEs Leading to Death, Grade ≥3 TEAEs, Any-Grade and Grade ≥3 TEAEs Related to Pertuzumab, and TEAEs to Monitor
timeFrame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Subgroup Analysis by ECOG Performance Status at Baseline: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab
timeFrame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Subgroup Analysis by Visceral Disease at Baseline: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab
timeFrame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Subgroup Analysis by Prior (Neo)Adjuvant Chemotherapy: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab
timeFrame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Subgroup Analysis by Hormone Receptor Status at Baseline: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab
timeFrame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Subgroup Analysis by Previous Trastuzumab Therapy: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab
timeFrame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Number of Participants With a Congestive Heart Failure Event
timeFrame: From Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Time to Onset of the First Episode of Congestive Heart Failure
timeFrame: From Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Values Over the Course of the Study
timeFrame: Baseline, predose on Day 1 of every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Number of Participants by Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Categories Over the Course of the Study
timeFrame: Baseline, predose on Day 1 of every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Number of Participants With Laboratory Abnormalities in Hematology and Coagulation Parameters: Shift From Baseline to the Worst Post-Baseline Grade According to NCI-CTC v4.0
timeFrame: Predose at each treatment cycle (1 cycle is 3 weeks) from Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Number of Participants With Laboratory Abnormalities in Hematology and Coagulation Parameters: Shift From Baseline to the Worst Post-Baseline Grade According to Normal Range Criteria
timeFrame: Predose at each treatment cycle (1 cycle is 3 weeks) from Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Number of Participants With Laboratory Abnormalities in Biochemistry Parameters: Shift From Baseline to the Worst Post-Baseline Grade According to NCI-CTC v4.0
timeFrame: Predose at each treatment cycle (1 cycle is 3 weeks) from Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Number of Participants With Laboratory Abnormalities in Biochemistry Parameters: Shift From Baseline to the Worst Post-Baseline Grade According to Normal Range Criteria
timeFrame: Predose at each treatment cycle (1 cycle is 3 weeks) from Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Secondary outcomes:
measure: Progression-Free Survival, as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
timeFrame: From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
measure: Subgroup Analysis by Region of Enrollment: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
timeFrame: From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
measure: Subgroup Analysis by Age (≤65 vs. >65 Years): Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
timeFrame: From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
measure: Subgroup Analysis by ECOG Performance Status at Baseline: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
timeFrame: From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
measure: Subgroup Analysis by Taxane Chemotherapy: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
timeFrame: From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
measure: Subgroup Analysis by Visceral Disease at Baseline: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
timeFrame: From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
measure: Subgroup Analysis by Prior (Neo)Adjuvant Chemotherapy: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
timeFrame: From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
measure: Subgroup Analysis by Hormone Receptor Status at Baseline: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
timeFrame: From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
measure: Subgroup Analysis by Previous Trastuzumab Therapy: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
timeFrame: From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
measure: Overall Survival
timeFrame: From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
measure: Subgroup Analysis by Region of Enrollment: Overall Survival
timeFrame: From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
measure: Subgroup Analysis by Age (≤65 vs. >65 Years): Overall Survival
timeFrame: From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
measure: Subgroup Analysis by ECOG Performance Status at Baseline: Overall Survival
timeFrame: From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
measure: Subgroup Analysis by Taxane Chemotherapy: Overall Survival
timeFrame: From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
measure: Subgroup Analysis by Visceral Disease at Baseline: Overall Survival
timeFrame: From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
measure: Subgroup Analysis by Prior (Neo)Adjuvant Chemotherapy: Overall Survival
timeFrame: From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
measure: Subgroup Analysis by Hormone Receptor Status at Baseline: Overall Survival
timeFrame: From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
measure: Subgroup Analysis by Previous Trastuzumab Therapy: Overall Survival
timeFrame: From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
measure: Overall Response Rate (Complete Response or Partial Response) Based on Best Overall Response (Confirmed) as Assessed by the Investigator Using RECIST v1.1
timeFrame: Assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter, until disease progression or death. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
measure: Percentage of Participants by Best Overall Response as Assessed by the Investigator Using RECIST v1.1
timeFrame: Assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter, until disease progression or death. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
measure: Subgroup Analysis by Age (≤65 vs. >65 Years): Overall Response Rate (Complete Response or Partial Response) Based on Best Overall Response (Confirmed) as Assessed by the Investigator Using RECIST v1.1
timeFrame: Assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter, until disease progression or death. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
measure: Subgroup Analysis by Taxane Chemotherapy: Overall Response Rate (Complete Response or Partial Response) Based on Best Overall Response (Confirmed) as Assessed by the Investigator Using RECIST v1.1
timeFrame: Assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter, until disease progression or death. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
measure: Clinical Benefit Rate (CR or PR, or SD for at Least 6 Months) Based on Best Overall Response as Assessed by the Investigator Using RECIST v.1.1
timeFrame: Assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter, until disease progression. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
measure: Duration of Response as Assessed by the Investigator Using RECIST v1.1
timeFrame: From date of first confirmed response (CR or PR) to first documented disease progression or death from any cause, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
measure: Time to Response for Participants With Best Overall Response of Complete Response or Partial Response, as Assessed by the Investigator Using RECIST v1.1
timeFrame: From date of first study treatment until date of first confirmed response (CR or PR). The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
measure: Change From Baseline in Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B) Questionnaire Total Score Over the Course of the Study
timeFrame: Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Change From Baseline in FACT-B Questionnaire Physical Well-Being Subscale Score Over the Course of the Study
timeFrame: Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Change From Baseline in FACT-B Questionnaire Social Well-Being Subscale Score Over the Course of the Study
timeFrame: Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Change From Baseline in FACT-B Questionnaire Emotional Well-Being Subscale Score Over the Course of the Study
timeFrame: Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Change From Baseline in FACT-B Questionnaire Functional Well-Being Subscale Score Over the Course of the Study
timeFrame: Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
measure: Change From Baseline in FACT-B Questionnaire Breast Cancer Subscale Score Over the Course of the Study
timeFrame: Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Other outcomes:
Locations:
city: Algiers
country: Algeria
facility: CPMC; Service d'Oncologie Médicale
city: La Rioja
country: Argentina
facility: Centro Oncologico Riojano Integral (CORI)
city: Rosario
country: Argentina
facility: Instituto de Oncología de Rosario
city: Canberra
country: Australia
facility: Canberra Hospital; Medical Oncology
state: Australian Capital Territory
city: Camperdown
country: Australia
facility: Royal Prince Alfred Hospital; Medical Oncology
state: New South Wales
city: Chermside
country: Australia
facility: HOCA Chermside
state: Queensland
city: South Brisbane
country: Australia
facility: Mater Hospital; Cancer Services
state: Queensland
city: Melbourne
country: Australia
facility: Austin and Repatriation Medical Centre; Cancer Services
state: Victoria
city: Parkville
country: Australia
facility: Royal Melbourne Hospital; Hematology and Medical Oncology
state: Victoria
city: Graz
country: Austria
facility: Lkh-Univ. Klinikum Graz; Klinik Für Gynäkologie
city: Graz
country: Austria
facility: LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie
city: Innsbruck
country: Austria
facility: Tiroler Landeskrankenanstalten Ges.M.B.H.; Abt. Für Gynäkologie
city: Linz
country: Austria
facility: Ordensklinikum Linz Barmherzige Schwestern; Abt. fur Innere Medizin 1
city: Salzburg
country: Austria
facility: Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.
city: Steyr
country: Austria
facility: A.Ö. Lhk; Ii. Medizinische Abt. Mit Schwerpunkt Gaströnter. & Onkologie
city: Wien
country: Austria
facility: Medizinische Universität Wien; Univ.Klinik für Frauenheilkunde - Klinik für Gynäkologie
city: Wien
country: Austria
facility: Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie
city: Brussel
country: Belgium
facility: UZ Brussel
city: Edegem
country: Belgium
facility: UZ Antwerpen
city: Gent
country: Belgium
facility: UZ Gent
city: Leuven
country: Belgium
facility: UZ Leuven Gasthuisberg
city: Liège
country: Belgium
facility: CHU Sart-Tilman
city: Rio de Janeiro
country: Brazil
facility: Oncologistas Associados
state: RJ
city: Porto Alegre
country: Brazil
facility: Hospital Sao Lucas - PUCRS
state: RS
city: Jau
country: Brazil
facility: Hospital Amaral Carvalho
state: SP
city: Sao Paulo
country: Brazil
facility: Hospital Sirio Libanes; Centro de Oncologia
state: SP
city: Sao Paulo
country: Brazil
facility: Hospital Perola Byington
state: SP
city: Sao Paulo
country: Brazil
facility: Hospital das Clinicas - FMUSP
state: SP
city: São Paulo
country: Brazil
facility: Hospital Sao Jose
state: SP
city: Edmonton
country: Canada
facility: Cross Cancer Institute ; Dept of Medical Oncology
state: Alberta
city: North Vancouver
country: Canada
facility: Lions Gate Hospital
state: British Columbia
city: Victoria
country: Canada
facility: Bcca - Vancouver Island Cancer Centre; Oncology
state: British Columbia
city: Halifax
country: Canada
facility: Queen Elizabeth II Health Sciences Centre; Oncology
state: Nova Scotia
city: Brampton
country: Canada
facility: William Osler Health System Brampton Civic Hospital
state: Ontario
city: Kitchener
country: Canada
facility: Grand River Hospital
state: Ontario
city: Toronto
country: Canada
facility: Sunnybrook Odette Cancer Centre
state: Ontario
city: Greenfield Park
country: Canada
facility: CSSS champlain - Charles-Le Moyne
state: Quebec
city: Montreal
country: Canada
facility: Centre Hospitalier de l'Université de Montréal (CHUM)
state: Quebec
city: Montreal
country: Canada
facility: McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology
state: Quebec
city: Beijing
country: China
facility: Beijing Cancer Hospital
city: Chongqing
country: China
facility: Southwest Hospital , Third Military Medical University
city: Guangzhou
country: China
facility: Sun Yet-sen University Cancer Center
city: Harbin
country: China
facility: Heilongjiang Provincial Tumor Hospital
city: Nanjing
country: China
facility: Jiangsu Cancer Hospital
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center
city: Tianjin
country: China
facility: Tianjin Cancer Hospital
city: Xi'an
country: China
facility: The First Affiliated Hospital of The Fourth Military Medical University (Xijing Hospital)
city: Xi'an
country: China
facility: First Affiliated Hospital of Medical College of Xi'an Jiaotong University
city: Portoviejo
country: Ecuador
facility: Hospital Solca Portoviejo; Oncologia
city: Quito
country: Ecuador
facility: Hospital Solca Quito; Oncologia
city: Cairo
country: Egypt
facility: Manial Specialized Hospital; Oncology
city: Cairo
country: Egypt
facility: El Mokatam HIO Hospital
city: Cairo
country: Egypt
facility: Nci; Oncology Dept
city: Tallinn
country: Estonia
facility: North Estonia Medical Centre Foundation; Oncology Center
city: Tartu
country: Estonia
facility: Tartu University Hospital; Clinic of Hematology and Oncology
city: Helsinki
country: Finland
facility: Helsinki University Central Hospital; Oncology Clinics
city: Pori
country: Finland
facility: Satakunta Central Hospital; Oncology
city: Tampere
country: Finland
facility: Tampere University Hospital; Dept of Oncology
city: Turku
country: Finland
facility: Turku Uni Central Hospital; Oncology Clinics
city: Amiens
country: France
facility: Clinique De L Europe; Radiotherapie Chimiotherapie
city: Angers
country: France
facility: ICO Paul Papin; Oncologie Medicale.
city: Bordeaux
country: France
facility: Polyclinique Bordeaux Nord Aquitaine; Chimiotherapie Radiotherapie
city: Bourg En Bresse
country: France
facility: Centre Hospitalier Fleyriat; Oncologie/Hematologie
city: Dechy
country: France
facility: Centre Leonard De Vinci;Chimiotherapie
city: Dijon
country: France
facility: Fondation Clement Drevon; Oncology
city: Dijon
country: France
facility: Centre Georges Francois Leclerc; Oncologie 3
city: Hyeres
country: France
facility: Clinique Sainte Marguerite; Oncologie Medicale
city: La Chaussee St Victor
country: France
facility: Polyclinique de Blois; Chimiotherapie Ambulatoire
city: LeMans
country: France
facility: Clinique Victor Hugo
city: Lille
country: France
facility: Polyclinique Du Bois; Centre Bourgogne
city: Limoges
country: France
facility: Clinique Chenieux; Oncology
city: Lyon
country: France
facility: Centre Leon Berard; Departement Oncologie Medicale
city: Marseille
country: France
facility: Institut Paoli Calmettes; Oncologie Medicale
city: Mougins
country: France
facility: Centre Azureen De Cancerologie; Cons externes
city: Paris
country: France
facility: Hopital Cochin; Unite Fonctionnelle D Oncologie
city: Paris
country: France
facility: Hopital Hotel Dieu; Oncologie Medicale
city: Paris
country: France
facility: Institut Curie; Oncologie Medicale
city: Paris
country: France
facility: Hopital Saint Louis; Service Onco Thoracique
city: Perpignan
country: France
facility: Centre Catalan D' Oncologie
city: Reims
country: France
facility: Polyclinique De Courlancy; Centre Radiotherapie Oncologie
city: Rennes
country: France
facility: Centre Eugene Marquis; Unite Huguenin
city: Saint Cloud
country: France
facility: Centre Rene Huguenin; ONCOLOGIE GENETIQUE
city: Saint Gregoire
country: France
facility: Chp Saint Gregoire; Cancerologie Radiotherapie
city: Saint Herblain
country: France
facility: Ico Rene Gauducheau; Oncologie
city: Strasbourg
country: France
facility: Institut D Oncologie Medical
city: Toulouse
country: France
facility: Institut Claudius Regaud; Departement Oncologie Medicale
city: Valence
country: France
facility: Hopital Prive Drome Ardeche; Hopital De Jour
city: Valenciennes
country: France
facility: Clinique Onco Des Dentellieres; Chimiotherapie Radiotherapie
city: Bamberg
country: Germany
facility: Klinikum am Bruderwald; Frauenklinik
city: Bremen
country: Germany
facility: Gynaekologicum Bremen; Prof. Dr. Willibald Schröder
city: Erlangen
country: Germany
facility: Universitätsklinikum Erlangen; Frauenklinik
city: Essen
country: Germany
facility: Universitätsklinikum Essen; Zentrum Für Frauenheilkunde
city: Esslingen
country: Germany
facility: Klinikum Esslingen; Klinik für Frauenheilkunde und Geburtshilfe
city: Frankfurt
country: Germany
facility: AGAPLESION Markus-Krankenhaus
city: Gera
country: Germany
facility: SRH Wald-Klinikum Gera; Klinik für Frauenheilkunde und Geburtshilfe
city: Hamburg
country: Germany
facility: Universitätsklinikum Hamburg-Eppendorf; Frauenklinik
city: Hannover
country: Germany
facility: Gynaekologisch-Onkologische Schwerpunktpraxis Prof. Dr. med. Lueck, Dr. Schrader und Dr. Noeding
city: Heidelberg
country: Germany
facility: Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg
city: Homburg/Saar
country: Germany
facility: Universitätsklinikum des Saarlandes; Klinik f. Frauenheilkunden und Geburtshilfe
city: Limburg
country: Germany
facility: St.-Vincenz-Krankenhaus; Frauenklinik
city: Lübeck
country: Germany
facility: Universitätsklinikum Schleswig-Holstein / Campus Lübeck; Klinik für Frauenheilkunde und Geburtshilfe
city: Mönchengladbach
country: Germany
facility: Brustzentrum Rhein-Ruhr Servicegesellschaft mbH
city: München
country: Germany
facility: Klinikum rechts der Isar der TU München; Klinik und Poliklinik für Frauenheilkunde
city: Neuruppin
country: Germany
facility: Ruppiner Kliniken, Klinik fuer Gynaekologie und Geburtshilfe
city: Rotenburg/Wümme
country: Germany
facility: Agaplesion Diakonieklinikum Rotenburg
city: Saarbruecken
country: Germany
facility: Praxis Dr. Wagner
city: Torgau
country: Germany
facility: Kreiskrankenhaus Torgau; Abt.Gynäkologie und Geburtshilfe
city: Tübingen
country: Germany
facility: Universitätsklinik Tübingen; Frauenklinik
city: Athens
country: Greece
facility: Anticancer Hospital Ag. Savas ; 2Nd Dept. of Oncology - Internal Medicine
city: Crete
country: Greece
facility: University General Hospital of Heraklion
city: Patras
country: Greece
facility: University Hospital of Patras Medical Oncology
city: Thessaloniki
country: Greece
facility: Euromedical General Clinic of Thessaloniki; Oncology Department
city: Thessaloniki
country: Greece
facility: Papageorgiou General Hospital; Medical Oncology
city: Αθηνα
country: Greece
facility: Hippokratio Hospital; 2Nd Internal Medicine
city: Λαρισα
country: Greece
facility: University Hospital of Larissa; Oncology
city: Hong Kong
country: Hong Kong
facility: Queen Elizabeth Hospital; Clinical Oncology
city: Budapest
country: Hungary
facility: Szent Margit Hospital; Dept. of Oncology
city: Budapest
country: Hungary
facility: Fovarosi Szent Laszlo Korhaz-Rendelointezet; Onkologiai Osztaly X
city: Budapest
country: Hungary
facility: Orszagos Onkologial Intezet; Onkologiai Osztaly X
city: Debrecen
country: Hungary
facility: Debreceni Egyetem Klinikai Kozpont ; Department of Oncology
city: Miskolc
country: Hungary
facility: Borsod-Abauj-Zemplen Megyei Korhaz Es Egyetemi Oktato Korhaz; Onkologiai Osztaly
city: Szeged
country: Hungary
facility: Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika
city: Beer Sheva
country: Israel
facility: Soroka Medical Center; Oncology Dept
city: Haifa
country: Israel
facility: Rambam Medical Center; Oncology
city: Holon
country: Israel
facility: Wolfson Hospital; Oncology
city: Jerusalem
country: Israel
facility: Shaare Zedek Medical Center; Oncology Dept
city: Jerusalem
country: Israel
facility: Hadassah Ein Karem Hospital; Oncology Dept
city: Nahariya
country: Israel
facility: Nahariya Hospital; Oncology
city: Petach Tikva
country: Israel
facility: Rabin Medical Center; Oncology Dept
city: Ramat Gan
country: Israel
facility: Chaim Sheba Medical Center; Oncology Dept
city: Rehovot
country: Israel
facility: Kaplan Medical Center; Oncology Inst.
city: Tel Aviv
country: Israel
facility: Sourasky / Ichilov Hospital; Dept. of Oncology
city: Tel Aviv
country: Israel
facility: Assuta Medical Centre; Oncology
city: Zerifin
country: Israel
facility: Assaf Harofeh; Oncology
city: Avellino
country: Italy
facility: Azienda Ospedaliera San Giuseppe Moscati
state: Campania
city: Piacenza
country: Italy
facility: Az. Osp. Ospedale Civile; U.O. Di Oncologia Medica Ed Ematologia
state: Emilia-Romagna
city: Ravenna
country: Italy
facility: Azienda USL di Ravenna; Unità Operativa di Oncologia Medica
state: Emilia-Romagna
city: Udine
country: Italy
facility: Azienda Ospedaliero-Universitaria Dipartimento Interaziendale Di Oncologia
state: Friuli-Venezia Giulia
city: Viterbo
country: Italy
facility: Ospedale Belcolle Di Viterbo; Oncologia
state: Lazio
city: Genova
country: Italy
facility: Ente Ospedaliero Ospedali Galliera; S.C. Oncologia Medica
state: Liguria
city: Bergamo
country: Italy
facility: Asst Papa Giovanni XXIII; Oncologia Medica
state: Lombardia
city: Legnago
country: Italy
facility: Ospedale Mater Salutis; Dept of Oncology
state: Lombardia
city: Milano
country: Italy
facility: Irccs Ospedale San Raffaele;Oncologia Medica
state: Lombardia
city: Milano
country: Italy
facility: Istituto Europeo Di Oncologia
state: Lombardia
city: Pavia
country: Italy
facility: Irccs Policlinico S. Matteo - Uni Pavia; Clinica Medica I Div. Med. Int. Onc. Medica E Gastroent.
state: Lombardia
city: Ancona
country: Italy
facility: Ospedali Riuniti Di Ancona; Oncology
state: Marche
city: Macerata
country: Italy
facility: Ospedale Di Macerata; Oncologia
state: Marche
city: Novara
country: Italy
facility: Ospedale Maggiore Della Carita; Oncologia Medica
state: Piemonte
city: Ponderano (BI)
country: Italy
facility: Ospedale Degli Infermi Di Biella; Reparto Oncologia Medica
state: Piemonte
city: Torino
country: Italy
facility: Fondazione Del Piemonte; Medical Oncology
state: Piemonte
city: Taormina
country: Italy
facility: Ospedale S. Vincenzo; Oncologia Medica
state: Sicilia
city: Firenze
country: Italy
facility: Azienda Ospedaliero-Universitaria Careggi;S.C. Oncologia Medica 1
state: Toscana
city: Cona (Ferrara)
country: Italy
facility: Arcispedale S.Anna; Oncologia Medica
state: Veneto
city: Beirut
country: Lebanon
facility: American University of Beirut - Medical Center
city: Beirut
country: Lebanon
facility: Hotel Dieu de France; Oncology
city: Kaunas
country: Lithuania
facility: Hospital of Lithuanian University of Health. Sciences Kaunas Clinics
city: Vilnius
country: Lithuania
facility: Uni Oncology Inst. ; Chemo - Radiation Dept
city: D.f.
country: Mexico
facility: Iem-Fucam
city: D.f.
country: Mexico
facility: Medica Sur Centro Oncologico Integral
city: Distrito Federal
country: Mexico
facility: Instituto Nacional de Cancerologia; Oncology
city: Mexico City
country: Mexico
facility: Consultorio de Medicina Especializada; Dentro de Condominio San Francisco
city: Mexico City
country: Mexico
facility: Centro Medico Nacional Siglo Xxi - Imss; Hospital de Oncologia
city: Mexico City
country: Mexico
facility: Instituto Nacional de Ciencias Médicas Y de La Nutricion Zubirán
city: Mexico DF
country: Mexico
facility: Hospital General de México; Unidad de Oncologia
city: Queretaro, Queretaro
country: Mexico
facility: Cancerologia de Queretaro; Oncologia
city: Rabat
country: Morocco
facility: Institut National D'oncologie Sidi Mohammed Ben Abdellah; Anatomopathologie
city: Alkmaar
country: Netherlands
facility: Medisch Centrum Alkmaar
city: Dordrecht
country: Netherlands
facility: Albert Schweitzer Ziekenhuis
city: Eindhoven
country: Netherlands
facility: Catharina ZKHS; Inwendige Geneeskunde Afd.
city: Groningen
country: Netherlands
facility: Martini Ziekenhuis; Dept of Internal Medicine
city: Leidschendam
country: Netherlands
facility: Mc Haaglanden, Locatie Antoniushove; Interne Geneeskunde
city: Rotterdam
country: Netherlands
facility: Ikazia Ziekenhuis; Interne Oncologie
city: Tilburg
country: Netherlands
facility: Twee Steden Ziekenhuis - Locatie Tilburg; Interne Geneesekunde
city: Venlo
country: Netherlands
facility: Vie Curie
city: Islamabad
country: Pakistan
facility: Shifa International Hospital; Department of Oncology
city: Lahore
country: Pakistan
facility: Shaukat Khanum Memorial Cancer Hospital; Department of Oncology
city: Lahore
country: Pakistan
facility: Hameed Latif Hospital; Department of Oncology
city: Lima
country: Peru
facility: Instituto;Oncologico Miraflores
city: Lima
country: Peru
facility: Clinica Internacional, Sede San Borja; Unidad de Investigacion de Clínica Internacional
city: Lima
country: Peru
facility: Hospital Nacional LNS dela Policia Nacional del Perú. Unidad Onco; Deapartamento de Oncología
city: Bialystok
country: Poland
facility: Bialostockie Centrum Onkologii; Oddzial Onkologii Klinicznej
city: Kielce
country: Poland
facility: Świętokrzyskie Centrum Onkologii; Dział Chemioterapii
city: Kraków
country: Poland
facility: Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Kliniki Onkologii
city: Lodz
country: Poland
facility: Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii; Poradnia Chemioterapii
city: Otwock
country: Poland
facility: Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina, Klinika Onkologii
city: Warszawa
country: Poland
facility: Cent.Onkologii-Instytut im. M. S-Curie, Klinika Now. Piersi i Chirurgii Rekon
city: Coimbra
country: Portugal
facility: IPO de Coimbra; Servico de Oncologia Medica
city: Evora
country: Portugal
facility: Hospital do Espirito Santo; Servico de Oncologia Medica
city: Lisboa
country: Portugal
facility: Centro Clinico Champalimaud; Oncologia Medica
city: Lisboa
country: Portugal
facility: Hospital da Luz; Departamento de Oncologia Medica
city: Lisboa
country: Portugal
facility: Hospital de Santa Maria; Servico de Oncologia Medica
city: Loures
country: Portugal
facility: Hospital Beatriz Angelo; Departamento de Oncologia
city: Porto
country: Portugal
facility: IPO do Porto; Servico de Oncologia Medica
city: Porto
country: Portugal
facility: Hospital de Sao Joao; Servico de Oncologia
city: Riyadh
country: Saudi Arabia
facility: King Faisal Specialist Hospital & Research Centre; Oncology
city: Riyadh
country: Saudi Arabia
facility: King Abdul Aziz Medical City, King Fahd National Guard; Oncology
city: Belgrade
country: Serbia
facility: Institute for Onc/Rad Serbia
city: Sremska Kamenica
country: Serbia
facility: Oncology Institute of Vojvodina
city: Ljubljana
country: Slovenia
facility: Institute of Oncology Ljubljana
city: Alcoy
country: Spain
facility: Hospital Virgen de los Lirios; Servicio de Oncologia
state: Alicante
city: Elda
country: Spain
facility: Hospital General de Elda; Servicio de Oncologia
state: Alicante
city: Gijon
country: Spain
facility: Hospital de Cabueñes; Servicio de Oncologia
state: Asturias
city: Sabadell
country: Spain
facility: Corporacio Sanitaria Parc Tauli; Servicio de Oncologia
state: Barcelona
city: Jerez de La Frontera
country: Spain
facility: Hospital de Jerez de la Frontera; Servicio de Oncologia
state: Cadiz
city: Castellon de La Plana
country: Spain
facility: Hospital Provincial de Castellon; Servicio de Oncologia
state: Castellon
city: Barbastro
country: Spain
facility: Hospital de Barbastro; Servicio de Oncologia
state: Huesca
city: Palma De Mallorca
country: Spain
facility: Hospital Universitario Son Espases
state: Islas Baleares
city: Santiago de Compostela
country: Spain
facility: Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia
state: LA Coruña
city: Logroño
country: Spain
facility: Complejo Hospitalario San Millan - San Pedro; Servicio de Oncologia
state: LA Rioja
city: Las Palmas de Gran Canaria
country: Spain
facility: Hospital Universitario Materno Infantil de Gran Canaria; Servicio de Oncologia
state: LAS Palmas
city: Las Palmas de Gran Canaria
country: Spain
facility: Hospital de Gran Canaria Dr. Negrin; Servicio de Oncologia
state: LAS Palmas
city: Alcorcon
country: Spain
facility: Fundacion Hospital de Alcorcon; Servicio de Oncologia
state: Madrid
city: Leganes
country: Spain
facility: Hospital Severo Ochoa; Servicio de Oncologia
state: Madrid
city: Pamplona
country: Spain
facility: Clinica Universitaria de Navarra; Servicio de Oncologia
state: Navarra
city: Reus
country: Spain
facility: Hospital Universitari Sant Joan de Reus; Servicio de Oncologia
state: Tarragona
city: Santa Cruz de Tenerife
country: Spain
facility: Complejo Hospitalario Nuestra Señora de la Candelaria; Servicio de Oncologia
state: Tenerife
city: Sagunto
country: Spain
facility: Hospital de Sagunto; Servicio de Oncologia
state: Valencia
city: Bilbao
country: Spain
facility: Hospital de Basurto; Servicio de Oncologia
state: Vizcaya
city: Barcelona
country: Spain
facility: Hospital Quiron Barcelona; Servicio de Oncologia
city: Barcelona
country: Spain
facility: Hospital Clínic i Provincial; Servicio de Hematología y Oncología
city: Barcelona
country: Spain
facility: Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia
city: Burgos
country: Spain
facility: Complejo Asistencial Universitario De Burgos; Servicio de Oncologia
city: Caceres
country: Spain
facility: Hospital San Pedro De Alcantara; Servicio de Oncologia
city: Girona
country: Spain
facility: Hospital Universitari de Girona Dr. Josep Trueta; Servicio de Oncologia
city: Granada
country: Spain
facility: Hospital Universitario Virgen de las Nieves; Servicio de Oncologia
city: Guadalajara
country: Spain
facility: Hospital General Universitario de Guadalajara; Servicio de Oncologia
city: Leon
country: Spain
facility: Complejo Asistencial Universitario de Leon; Servicio de Oncologia
city: Madrid
country: Spain
facility: Centro Oncologico MD Anderson Internacional; Servicio de Oncologia
city: Madrid
country: Spain
facility: Hospital Ramon y Cajal; Servicio de Oncologia
city: Madrid
country: Spain
facility: Fundacion Jimenez Diaz; Servicio de Oncologia
city: Madrid
country: Spain
facility: Hospital Universitario Clínico San Carlos; Servicio de Oncologia
city: Madrid
country: Spain
facility: Hospital Universitario 12 de Octubre; Servicio de Oncologia
city: Madrid
country: Spain
facility: Hospital Universitario La Paz; Servicio de Oncologia
city: Madrid
country: Spain
facility: HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia
city: Malaga
country: Spain
facility: Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia
city: Murcia
country: Spain
facility: Hospital General Universitario J.M Morales Meseguer; Servicio de Oncologia
city: Murcia
country: Spain
facility: Hospital Universitario Virgen de Arrixaca; Servicio de Oncologia
city: Navarra
country: Spain
facility: Hospital de Navarra; Servicio de Oncologia
city: Orense
country: Spain
facility: Complejo Hospitalario de Orense; Servicio de Oncologia
city: Salamanca
country: Spain
facility: Hospital Clinico Universitario de Salamanca; Servicio de Oncologia
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen Macarena; Servicio de Oncologia
city: Valencia
country: Spain
facility: Hospital Arnau de Vilanova (Valencia) Servicio de Oncologia
city: Valencia
country: Spain
facility: Hospital Universitario Dr. Peset
city: Valladolid
country: Spain
facility: Hospital Clinico Universitario de Valladolid; Servicio de Oncologia
city: Valladolid
country: Spain
facility: Hospital de Rio Hortega; Servicio de Oncologia
city: Zaragoza
country: Spain
facility: Hospital Clinico Universitario Lozano Blesa; Servicio de Oncologia
city: Zaragoza
country: Spain
facility: Hospital Universitario Miguel Servet; Servicio Oncologia
city: Gävle
country: Sweden
facility: Gävle Sjukhus; Onkologiska Kliniken
city: Göteborg
country: Sweden
facility: Sahlgrenska Universitetssjukhuset; Jubileumskliniken
city: Karlstad
country: Sweden
facility: Centralsjukhuset Karlstad, Onkologkliniken
city: Lund
country: Sweden
facility: Skånes University Hospital, Skånes Department of Onclology
city: Vaxjo
country: Sweden
facility: Centrallasarettet Växjö, Onkologkliniken
city: Västerås
country: Sweden
facility: Västmanlands sjukhus Västerås, Onkologkliniken
city: Adana
country: Turkey
facility: Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology
city: Antalya
country: Turkey
facility: Akdeniz University Medical Faculty; Medical Oncology Department
city: Bornova, İ̇zmi̇r
country: Turkey
facility: Ege University Medical Faculty; Medical Oncology Department
city: Edirne
country: Turkey
facility: Trakya University Medical Faculty Research And Practice Hospital Medical Oncology Department
city: Sihhiye/Ankara
country: Turkey
facility: Hacettepe Uni Medical Faculty Hospital; Oncology Dept
city: Dnipropetrovsk
country: Ukraine
facility: Mun. Multifield Clin.Hosp.#4,Dept. of Chemotherapy, DSMU; Chair of Oncology and Medical Radiology
city: Kiev
country: Ukraine
facility: Kyiv City Clinical Oncological Center; Chemotherapy Department
city: Lviv
country: Ukraine
facility: State Oncology Regional Treatment-Diagnostic Center; Chemotherapy Department
city: Zaporozhye
country: Ukraine
facility: Zaporozhye Regional Oncology Hospital; Dept of Oncology
city: Al Ain
country: United Arab Emirates
facility: Tawam Hospital
city: Bath
country: United Kingdom
facility: Royal United Hospital; Oncology Department
city: Birmingham
country: United Kingdom
facility: City Hospital NHS Trust
city: Bristol
country: United Kingdom
facility: Bristol Haematology and Oncology Centre
city: Cambridge
country: United Kingdom
facility: Addenbrookes Hospital; Dept of Oncology
city: Cardiff
country: United Kingdom
facility: Velindre Hospital
city: Coventry
country: United Kingdom
facility: Walsgrave Hospital
city: Derby
country: United Kingdom
facility: Royal Derby Hospital
city: Durham
country: United Kingdom
facility: University Hospital of North Durham
city: East Kilbride
country: United Kingdom
facility: Hairmyres Hospital; Oncology Dept
city: Eastbourne
country: United Kingdom
facility: Eastbourne District Hospital; Department of Pharmacy
city: Glasgow
country: United Kingdom
facility: Beatson West of Scotland Cancer Centre
city: Grimsby
country: United Kingdom
facility: Diana Princess of Wales Hosp.
city: Guildford
country: United Kingdom
facility: Royal Surrey County Hospital
city: Leeds
country: United Kingdom
facility: Leeds Teaching Hosp NHS Trust;St James's Institute of Onc
city: Lindley
country: United Kingdom
facility: Huddersfield Royal Infirmary - Pharmacy department
city: London
country: United Kingdom
facility: Barts and the London NHS Trust.
city: London
country: United Kingdom
facility: Royal Free Hospital; Dept of Oncology
city: London
country: United Kingdom
facility: Kings College Hospital NHS Foundation Trust
city: London
country: United Kingdom
facility: Royal Marsden Hospital - London
city: Macclesfield
country: United Kingdom
facility: Macclesfield District General Hospital
city: Manchester
country: United Kingdom
facility: Christie Hospital; Breast Cancer Research Office
city: Middlesborough
country: United Kingdom
facility: James Cook Uni Hospital
city: New Castle Upon Tyne
country: United Kingdom
facility: Freeman Hospital; Northern Centre For Cancer Care
city: Northwood
country: United Kingdom
facility: Mount Vernon Cancer Centre
city: Oxford
country: United Kingdom
facility: Churchill Hospital
city: Peterborough
country: United Kingdom
facility: Peterborough City Hospital
city: Plymouth
country: United Kingdom
facility: Derriford Hospital; Plymouth Oncology Centre
city: Somerset
country: United Kingdom
facility: Musgrove Park Hospital
city: Sutton
country: United Kingdom
facility: The Royal Marsden Hospital
city: Truro
country: United Kingdom
facility: Royal Cornwall Hospital
city: Wishaw
country: United Kingdom
facility: Wishaw General Hospital
city: Montevideo
country: Uruguay
facility: Grupo Oncológico Cooperativo Uruguayo; Hospital de Clínicas - Dpto. de Oncología
city: Montevideo
country: Uruguay
facility: Hospital Central De Las FF.AA.; Servicio De Oncologia
city: Montevideo
country: Uruguay
facility: Hospital Pereira Rossell; Oncology Department
city: Caracas
country: Venezuela
facility: Centro Integral de Oncología
city: Caracas
country: Venezuela
facility: Centro Médico Docente La Trinidad; Servicio de Gastroenterología
Study officials:
affiliation: Hoffmann-La Roche
name: Clinical Trials
role: STUDY_DIRECTOR
References:
citation: Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, Easton V, Lindegger N, Miles D; PERUSE investigators. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Ann Oncol. 2019 May 1;30(5):766-773. doi: 10.1093/annonc/mdz061.